Published on 22/12/2025
Regulatory Requirements for Reporting Immunogenicity Data
What Regulators Expect Across Protocol, SAP, and CSR
Immunogenicity readouts drive dose and schedule selection, immunobridging, and—frequently—support accelerated or conditional approvals. Regulators expect to see a coherent story that links what you measure to why it matters and how it was analyzed. In the protocol, define your primary and key secondary endpoints (e.g., ELISA IgG geometric mean titer [GMT] at Day 35; neutralization ID50 GMT; seroconversion rate [SCR]) and the visit windows (e.g., Day 35 ±2, Day 180 ±14). State clinical case definitions that determine which participants enter immunogenicity sets (e.g., infection between doses) and specify handling of intercurrent events. In the SAP, lock the statistical model (ANCOVA on log10 titers with baseline and site as covariates; Miettinen–Nurminen CIs for SCR), multiplicity control (gatekeeping vs Hochberg), and non-inferiority margins (e.g., GMT ratio lower bound ≥0.67; SCR difference ≥−10%). The lab manual must declare fit-for-purpose assay parameters (LLOQ/ULOQ/LOD), plate acceptance rules, and reference standards. Finally, the CSR ties it together: prespecified shells, raw-to-table traceability, sensitivity analyses, and a rationale for how the data support labeling or bridging.
Two common gaps sink timelines: (1) inconsistency between protocol text and SAP shells,
Assay Validation and Standardization: LOD/LLOQ/ULOQ, Controls, and Calibration
Because dose and schedule decisions hinge on immune readouts, assay fitness is not optional. Declare and justify analytical limits in the lab manual and SAP, and keep them constant across sites and time. Typical parameters include ELISA IgG: LLOQ 0.50 IU/mL, ULOQ 200 IU/mL, LOD 0.20 IU/mL; pseudovirus neutralization: reportable range 1:10–1:5120 with values <1:10 imputed as 1:5 for analysis; ELISpot IFN-γ: LLOQ 10 spots/106 PBMC, ULOQ 800, precision ≤20% CV. Predefine how to treat out-of-range values (re-assay at higher dilutions or cap at ULOQ), replicate rules, curve fitting (4PL/5PL), and acceptance windows for controls (e.g., positive control ID50 target 1:640; accept 1:480–1:880; CV ≤20%). Calibrate to WHO International Standards where available to enable cross-lab comparability and pooled analyses. When any critical input changes (cell line, antigen lot, pseudovirus prep), execute a documented bridging panel (e.g., 50–100 sera spanning the titer range) with predefined acceptance criteria.
| Assay | Reportable Range | LLOQ | ULOQ | LOD | Precision Target |
|---|---|---|---|---|---|
| ELISA IgG | 0.20–200 IU/mL | 0.50 | 200 | 0.20 | ≤15% CV |
| Pseudovirus ID50 | 1:10–1:5120 | 1:10 | 1:5120 | 1:8 | ≤20% CV |
| ELISpot IFN-γ | 10–800 spots | 10 | 800 | 5 | ≤20% CV |
Regulators will also ask whether the clinical product and testing environment stayed state-of-control. Although clinical teams do not compute manufacturing toxicology, referencing representative PDE (e.g., 3 mg/day for a residual solvent) and cleaning MACO (e.g., 1.0–1.2 µg/25 cm2 surface swab) examples in the quality narrative helps ethics committees and inspection teams see that lot quality cannot explain immunogenicity differences across arms, sites, or time.
Endpoints, Estimands, and Multiplicity: Writing What You Intend to Prove
Regulatory reviewers look first for clarity of the scientific question and error control. Define co-primaries when appropriate—e.g., GMT at Day 35 and SCR (≥4× rise or threshold such as ID50 ≥1:40)—and pre-state the gatekeeping order (e.g., test GMT non-inferiority first, then SCR). Choose estimands that match reality: for immunobridging, a treatment-policy estimand may include participants regardless of intercurrent infection; a hypothetical estimand might exclude peri-infection windows. Multiplicity across markers (ELISA, neutralization), ages, and timepoints should be controlled (hierarchical testing, Hochberg, or alpha-spending if there are interims). For continuous endpoints, analyze log10 titers via ANCOVA with baseline and site/region as covariates; back-transform to report ratios and two-sided 95% CIs. For binary endpoints like SCR, use Miettinen–Nurminen CIs and stratify by key factors (e.g., baseline serostatus). Document handling rules for missing visits (multiple imputation stratified by site/age), out-of-window draws (e.g., Day 35 ±2 included; sensitivity excluding ±>2), and above/below quantification limits.
| Objective | Criterion | Action |
|---|---|---|
| NI on GMT | Lower 95% CI of ratio ≥0.67 | Proceed to SCR NI test |
| NI on SCR | Difference ≥−10% | Select dose if safety acceptable |
| Durability | ≥70% above ID50 1:40 at Day 180 | Defer booster; monitor Day 365 |
Tie your statistical plan to operations: DSMB pausing rules (e.g., ≥5% Grade 3 systemic AEs within 72 h) and firewall processes must be documented. Align analysis shells with raw datasets and provide checksums in the CSR. When adult–pediatric bridging or variant-adapted boosters are anticipated, state the thresholds and NI margins up front to avoid post-hoc debates.
Data Handling and Traceability: ALCOA, Raw-to-Table Line of Sight, and Inspection Readiness
Inspection-ready immunogenicity reporting is built on traceability. Regulators will “follow a sample” from the participant’s vein to the CSR table. Make ALCOA obvious: attributable specimen IDs and plate files; legible curve reports; contemporaneous QC logs; original raw exports under change control; and accurate tables programmatically generated from locked analysis datasets. Your TMF should include the lab manual, assay validation summary, method-transfer reports, proficiency testing, drift investigations, and CAPA, all version-controlled. Harmonize eCRF fields with analysis needs (e.g., baseline serostatus, sampling times, antipyretic use) and ensure EDC time-stamps align with visit windows (Day 35 ±2). For multi-country networks, qualify couriers and central labs; standardize pre-analytics (clot 30–60 minutes, centrifuge 1,300–1,800 g for 10 minutes, freeze at −80 °C within 4 hours, ≤2 freeze–thaw cycles) and maintain a lot register for critical reagents.
| Artifact | Where Filed | Inspector’s Question | Ready? |
|---|---|---|---|
| Plate maps & raw luminescence | TMF – Lab Records | Show acceptance and repeats | Yes |
| Curve reports & 4PL settings | TMF – Validation | Confirm fixed rules | Yes |
| Control trend charts | TMF – QC | Drift detection & CAPA | Yes |
| Analysis programs & checksums | TMF – Stats | Reproducible tables | Yes |
Close the loop with product quality context: state that clinical lots used across periods and regions were comparable and remained within labeled shelf-life. For completeness in ethics and inspection narratives, reference representative PDE (e.g., 3 mg/day) and cleaning validation MACO limits (e.g., 1.0–1.2 µg/25 cm2) so reviewers understand that neither residuals nor cross-contamination plausibly explain immune readouts. Where long-term durability is evaluated, confirm sample stability claims and time-out-of-freezer rules with quarantine/disposition logic.
Case Study (Hypothetical): Repairing an Immunogenicity Reporting Gap Before Filing
Context. A Phase II/III program discovered, during pre-submission QC, that one regional lab switched ELISA capture antigen lots mid-study without a bridging memo. The region’s Day-35 GMTs trended ~15% lower than others despite similar neutralization titers.
Action. The sponsor triggered the drift SOP: (1) quarantine affected plates; (2) run a 60-specimen blinded bridging panel covering 0.5–200 IU/mL and 1:10–1:5120 titers across all labs; (3) perform Deming regression and Bland-Altman analyses; (4) update the SAP with a pre-specified sensitivity excluding the affected window; and (5) document a comparability statement linking clinical lots and analytical methods. Investigations found suboptimal coating efficiency. CAPA included retraining, re-coating, recalibration to WHO standard, and a small scaling adjustment justified by the bridging slope.
| Metric | Pre-CAPA | Target | Post-CAPA |
|---|---|---|---|
| Inter-lab GMR (ELISA) | 0.84 | 0.80–1.25 | 0.98 |
| Positive control CV | 24% | ≤20% | 16% |
| Neutralization slope | 0.91 | 0.90–1.10 | 1.02 |
Outcome. The CSR narrative presents primary results, sensitivity excluding the affected interval, and the bridging memo. Conclusions hold, the TMF contains the full audit trail, and submission proceeds without a major clock-stop. The key lesson: immunogenicity reporting is not just tables—it’s governance, comparability, and documentation.
Templates, Checklists, and Packaging for Submission
Before you hit “publish,” align content to eCTD and reviewer workflows. In Module 2, summarize immunogenicity objectives, endpoints, and results with cross-references to methods and sensitivity analyses; in Module 5, provide full TLFs, validation summaries, and raw-to-analysis traceability. Include reverse cumulative distribution plots, waterfall plots for thresholds (e.g., ID50 ≥1:40), and subgroup summaries (age, baseline serostatus). Provide clear justifications for non-inferiority margins and multiplicity control, and ensure shells match outputs exactly. For programs with pediatric bridging or variant-adapted boosters, pre-define acceptance criteria in the protocol/SAP and echo them in the CSR. Maintain a living “assay governance” memo listing owners, change-control gates, and decision logs; inspectors appreciate a single map of accountability.
Take-home. Regulatory-grade immunogenicity reporting rests on four pillars: validated assays with explicit limits; prespecified endpoints and estimands with error control; end-to-end traceability (ALCOA) from plate file to CSR; and quality narratives that rule out non-biological confounders (e.g., PDE/MACO context, lot comparability). Build these elements early and keep them synchronized across protocol, SAP, lab manuals, and CSR. The result is evidence that travels smoothly from clinic to label—and stands up in an inspection.